Abstract | OBJECTIVE: METHODS: 154 type 2 diabetes patients with the level of blood glucose poorly controlled formerly were enrolled and treated with Diamicron MR for 16 weeks. The efficacy of slow-release- gliclazide was evaluated through HbA1c, FPG and 2 h PBG after 16 weeks of treatment period. The safety was evaluated through the adverse events including hypoglycemic episodes and the change of vital signs and clinic laboratory parameters. RESULTS: After 16 weeks of treatment period, the HbA1c, FPG and 2 h PBG were decreased by 1.89%, 2.31 mmol/L and 3.94 mmol/L respectively, cutting down 21.6%, 24.5% and 27.8% relatively in comparison with pre-treatment. Glucose metabolism could be significantly improved by taking once-daily Diamicron MR. CONCLUSION:
|
Authors | Wei-ping Jia, Guang Ning, Xin Gao, Li Yan, Hua-zhang Yang, Ming Li, Jie Hong, Zhi-qiang Lu, Hua Cheng, Yi-qin Qi, Zhong-wen Li, Kun-san Xiang |
Journal | Zhonghua yi xue za zhi
(Zhonghua Yi Xue Za Zhi)
Vol. 85
Issue 37
Pg. 2636-9
(Sep 28 2005)
ISSN: 0376-2491 [Print] China |
PMID | 16321325
(Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)
|
Chemical References |
- Hypoglycemic Agents
- Gliclazide
|
Topics |
- Adult
- Diabetes Mellitus, Type 2
(drug therapy)
- Female
- Gliclazide
(administration & dosage, therapeutic use)
- Humans
- Hypoglycemic Agents
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Prospective Studies
- Treatment Outcome
|